{"id":"W2603044866","doi":"10.1200/jco.2017.35.4_suppl.tps213","title":"Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec","funders":"","keywords":"Medicine; Nivolumab; Oxaliplatin; Internal medicine; Ipilimumab; Cancer; Oncology; Phases of clinical research; Chemotherapy; Gastroenterology; Immunotherapy; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003526442,0.0004522796,0.005041246,0.0004149984,0.0001677329,0.00007304978,0.0007710338,0.0001699118,0.0003736353],"category_scores_gemma":[0.006353653,0.0002649722,0.0002939298,0.0003996088,0.0003598337,0.0006578718,0.0003415354,0.0009212469,0.000005905172],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00121185,"about_ca_system_score_gemma":0.002424726,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001113115,"about_ca_topic_score_gemma":0.003597179,"domain_scores_codex":[0.9927409,0.001008216,0.004255929,0.0005278055,0.0008808246,0.000586327],"domain_scores_gemma":[0.9892353,0.001874752,0.00697,0.000648408,0.0008365432,0.0004350265],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8603674,0.01504001,0.03183706,0.0001706078,0.002143394,0.001332867,0.0004537438,0.0004143347,0.000008174396,0.000002214602,0.0004214836,0.08780867],"study_design_scores_gemma":[0.8290215,0.1159698,0.04610084,0.0004915505,0.004177151,0.00003727033,0.0008649703,0.002925897,0.00001236376,0.000002936682,0.0002209442,0.0001747692],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922404,0.0001733923,0.0001884832,0.0005010947,0.002027743,0.004590579,0.00001337194,0.00001733931,0.0002476202],"genre_scores_gemma":[0.9922906,0.0008945106,0.005064551,0.0001800307,0.000287455,0.0001313664,0.0000152584,0.00005094325,0.001085358],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1009298,"threshold_uncertainty_score":0.9999803,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.179962240909258,"score_gpt":0.4946128004632462,"score_spread":0.3146505595539882,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}